Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MNK
CUSIPN/A
Phone44-0-17-8463-6700
Debt
Debt-to-Equity Ratio0.98
Current Ratio2.27
Quick Ratio2.06
Price-To-Earnings
Trailing P/E Ratio4.82
Forward P/E Ratio5.37
P/E Growth0.58
Sales & Book Value
Annual Sales$3.22 billion
Price / Sales0.93
Cash Flow$16.8084 per share
Price / Cash2.14
Book Value$68.65 per share
Price / Book0.52
Profitability
EPS (Most Recent Fiscal Year)$7.49
Net Income$2.13 billion
Net Margins59.85%
Return on Equity10.39%
Return on Assets4.22%
Miscellaneous
Employees3,900
Outstanding Shares83,210,000
Market Cap$2.89 billion
Mallinckrodt (NYSE:MNK) Frequently Asked Questions
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How will Mallinckrodt's stock buyback program work?
Mallinckrodt announced that its Board of Directors has initiated a stock repurchase plan on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 18.5% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its stock is undervalued.
How were Mallinckrodt's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) posted its earnings results on Tuesday, August, 7th. The company reported $1.78 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.48 by $0.30. The firm earned $631.70 million during the quarter, compared to analyst estimates of $621.15 million. Mallinckrodt had a return on equity of 10.39% and a net margin of 59.85%. View Mallinckrodt's Earnings History.
When is Mallinckrodt's next earnings date?
What guidance has Mallinckrodt issued on next quarter's earnings?
Mallinckrodt issued an update on its FY18 earnings guidance on Tuesday, August, 7th. The company provided earnings per share (EPS) guidance of $6.50-6.90 for the period, compared to the Thomson Reuters consensus estimate of $6.23.
What price target have analysts set for MNK?
19 equities research analysts have issued 12 month target prices for Mallinckrodt's stock. Their predictions range from $15.00 to $58.00. On average, they anticipate Mallinckrodt's share price to reach $33.2632 in the next year. This suggests that the stock has a possible downside of 7.5%. View Analyst Price Targets for Mallinckrodt.
What is the consensus analysts' recommendation for Mallinckrodt?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 1 sell rating, 13 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.
What are Wall Street analysts saying about Mallinckrodt stock?
Here are some recent quotes from research analysts about Mallinckrodt stock:
- 1. Canaccord Genuity analysts commented, "We were pleasantly surprised by Mallinckrodt’s 2Q/18 beat and raise last week as the story continues to evolve toward higher pipeline science and away from Acthar- related drama. However, with strong momentum behind MNK shares of late, we remain concerned about external forces on Acthar or internal pipeline setbacks potentially squelching momentum in the story." (8/13/2018)
- 2. Cantor Fitzgerald analysts commented, ". Post a beat and raise quarter, we are reiterating our OW rating and $42 12-month price target for MNK shares. We believe that concerns regarding its long-term growth potential are overdone and that the company gets little-to-no credit for its pipeline. Therefore, upward earnings revisions and multiple expansion in 2020+ could drive the shares higher, in our view. MNK shares are trading +23% intraday." (8/7/2018)
- 3. Mizuho analysts commented, "We plan to remove all risk-adjusted estimates for this compound from our model after the earnings call, which will be somewhat offset by the greater than $0.15-$0.20 in dilution to adjusted earnings expected in 2018″." (5/3/2018)
- 4. According to Zacks Investment Research, "Mallinckrodt is selling its hemostasis products for Baxter. The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business.Mallinckrodt is facing challenging conditions as lead drug Acthar sales declined on volume while weaknesses in the generics segment persist. Acthar declined as specialty drugs face payer environment and the decline is expected to continue in the fourth quarter as well. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Shares of the company have underperformed the industry in the last six months. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax. As a result, Mallinckrodt is looking to diversify its portfolio with the recently announced Sucampo acquisition and counter the decline in existing drugs." (1/9/2018)
Are investors shorting Mallinckrodt?
Mallinckrodt saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 26,843,478 shares, a drop of 16.0% from the July 13th total of 31,948,114 shares. Based on an average trading volume of 2,067,830 shares, the short-interest ratio is currently 13.0 days. Approximately 32.8% of the company's stock are sold short. View Mallinckrodt's Current Options Chain.
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Perrigo (PRGO), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Beigene (BGNE), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amneal Pharmaceuticals (AMRX), Dr.Reddy's Laboratories (RDY) and United Therapeutics (UTHR).
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the folowing people:
- Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 57)
- Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 48)
- Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 49)
- Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 55)
- Ms. Kathleen A. Schaefer, Sr. VP, Principal Accounting Officer & Corp. Controller
Has Mallinckrodt been receiving favorable news coverage?
News stories about MNK stock have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Mallinckrodt earned a media and rumor sentiment score of 0.20 on Accern's scale. They also assigned headlines about the company an impact score of 47.42 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Mallinckrodt.
Who are Mallinckrodt's major shareholders?
Mallinckrodt's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.61%), Scopia Capital Management LP (9.22%), Dimensional Fund Advisors LP (5.32%), Miller Value Partners LLC (4.01%), LSV Asset Management (3.22%) and FMR LLC (2.78%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, James E Flynn, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.
Which institutional investors are selling Mallinckrodt stock?
MNK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Scopia Capital Management LP, Connor Clark & Lunn Investment Management Ltd., Schroder Investment Management Group, SG Americas Securities LLC, Trexquant Investment LP, FMR LLC and State Board of Administration of Florida Retirement System. View Insider Buying and Selling for Mallinckrodt.
Which institutional investors are buying Mallinckrodt stock?
MNK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Miller Value Partners LLC, First Trust Advisors LP, Dimensional Fund Advisors LP, Commonwealth Bank of Australia, Eqis Capital Management Inc., Royce & Associates LP and James Investment Research Inc.. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.
How do I buy shares of Mallinckrodt?
Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mallinckrodt's stock price today?
One share of MNK stock can currently be purchased for approximately $35.97.
How big of a company is Mallinckrodt?
Mallinckrodt has a market capitalization of $2.89 billion and generates $3.22 billion in revenue each year. The company earns $2.13 billion in net income (profit) each year or $7.49 on an earnings per share basis. Mallinckrodt employs 3,900 workers across the globe.
How can I contact Mallinckrodt?
Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]
MarketBeat Community Rating for Mallinckrodt (NYSE MNK)
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
